Search by Drug Name or NDC
NDC 72187-0401-01 Elzonris 1000 ug/mL Details
Elzonris 1000 ug/mL
Elzonris is a INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Stemline Therapeutics, Inc.. The primary component is TAGRAXOFUSP.
MedlinePlus Drug Summary
Tagraxofusp-erzs injection is used to treat blastic plasmacytoid dendritic cell neoplasm (BPDCN; a blood cancer that causes skin lesions, and may spread to the bone marrow and lymphatic system) in adults and children 2 years of age and older. Tagraxofusp-erzs is in a class of medications called CD123 cytotoxin. It works by killing cancer cells.
Related Packages: 72187-0401-01Last Updated: 12/01/2022
MedLinePlus Full Drug Details: Tagraxofusp-erzs Injection
Product Information
| NDC | 72187-0401 |
|---|---|
| Product ID | 72187-0401_fb0fe1fc-42ab-4a79-a73d-7f2999af9786 |
| Associated GPIs | 21703080302020 |
| GCN Sequence Number | 079401 |
| GCN Sequence Number Description | tagraxofusp-erzs VIAL 1000MCG/ML INTRAVEN |
| HIC3 | V39 |
| HIC3 Description | ANTINEOPLASTIC-CD123-DIRECTED CYTOTOXIN CONJUGATE |
| GCN | 45879 |
| HICL Sequence Number | 045555 |
| HICL Sequence Number Description | TAGRAXOFUSP-ERZS |
| Brand/Generic | Brand |
| Proprietary Name | Elzonris |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | tagraxofusp |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 1000 |
| Active Ingredient Units | ug/mL |
| Substance Name | TAGRAXOFUSP |
| Labeler Name | Stemline Therapeutics, Inc. |
| Pharmaceutical Class | CD123 Interaction [EPC], CD123 Interactions [MoA], Cytotoxin [EPC], Cytotoxins [CS] |
| DEA Schedule | n/a |
| Marketing Category | BLA |
| Application Number | BLA761116 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 72187-0401-01 (72187040101)
| NDC Package Code | 72187-0401-1 |
|---|---|
| Billing NDC | 72187040101 |
| Package | 1 VIAL, SINGLE-DOSE in 1 CARTON (72187-0401-1) / 1 mL in 1 VIAL, SINGLE-DOSE |
| Marketing Start Date | 2019-01-18 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |